Early ADME data are integrated with biomarker discovery through an exposure-driven, translational approach that links pharmacokinetics, target engagement, and biological response. In vitro ADME data are used to predict in vivo PK and guide compound selection, while in vivo PK studies confirm exposure–time relationships across species. This PK understanding informs the design of relevant toxicology studies at clinically meaningful exposures and the selection of in vivo efficacy models in which biomarker or PD readouts can be quantitatively correlated with systemic or tissue exposure.

By integrating exposure, biomarker response, and emerging safety signals into early PK/PD models, teams can estimate safety margins and construct more accurate therapeutic window projections prior to lead candidate nomination and clinical entry.

BioDuro supports biotechs during lead optimization by contributing to compound design, synthetic route development, biological evaluation, and DMPK profiling. In addition, our platforms with catalyst screening, photochemistry, flow chemistry and library synthesis enablement allows for rapid problem solving to move projects forward. 

Single site location for cross-functional collaboration between discovery chemistry, biology, and pharmacokinetics allows for reduced cycle time and timely data generation, allowing for rapid decision-making. This integrated approach, with a single project manager POC, also enables efficient progression from lead optimization to preclinical candidate selection, including the ability to conduct in vivo PK and PK/PD studies when appropriate.

Involving a CDMO like BioDuro at the stage of preclinical candidate selection is often beneficial. This is the appropriate time to introduce the compound to the process development and pre-formulation teams, who can begin evaluating manufacturability and formulation strategies. Early involvement helps reduce later-stage risks and supports a smoother handoff into IND-enabling studies.